{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-021231","form_type":"8-K","ticker":"PURE","cik":"0001006028","company_name":"PURE BIOSCIENCE, INC.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.555046+00:00","generated_at":"2026-06-14T00:49:24.131006+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"PURE Bioscience Q3 net product sales down 18% YoY to $406K; net loss widens to $876K","bullets":["Net product sales $406K in Q3 FY2023 vs $497K prior year, down 18% on decreased distribution sales.","Q3 net loss $876K vs $760K prior year; net loss per share flat at ($0.01).","Nine-month net product sales $1.27M vs $1.41M; net loss $2.93M vs $2.26M prior year.","CEO cites key distributor downturn; food division sales partially offset; new sales program initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-021231","json":"https://secwatch.observer/filing/0001493152-23-021231.json","markdown":"https://secwatch.observer/filing/0001493152-23-021231.md","text":"https://secwatch.observer/filing/0001493152-23-021231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006028/000149315223021231/0001493152-23-021231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006028/000149315223021231/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T00:49:24.131006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"198974572e1aa3dca9ca928b7ed5e12a9707dc51","claim":"PURE BIOSCIENCE, INC. reported the fiscal third quarter ended April 30, 2023 results: revenue $406,000, net income $876,000, EPS ($0.01).","evidence_excerpt":"Net product sales were $406,000 and $497,000 for the fiscal third quarters ended April 30, 2023 and 2022, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006028/000149315223021231/0001493152-23-021231-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal third quarter ended April 30, 2023"},{"label":"Revenue","value":"$406,000"},{"label":"Net income","value":"$876,000"},{"label":"EPS","value":"($0.01)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"95c1ac432edf2d35746b8df4f62dcd74d39d1da2","claim":"PURE BIOSCIENCE, INC. reported the nine months ended April 30, 2023 results: revenue $1,269,000, net income $2,929,000, EPS ($0.03).","evidence_excerpt":"Net product sales were $1,269,000 and $1,409,000 for the nine months ended April 30, 2023 and 2022, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006028/000149315223021231/0001493152-23-021231-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended April 30, 2023"},{"label":"Revenue","value":"$1,269,000"},{"label":"Net income","value":"$2,929,000"},{"label":"EPS","value":"($0.03)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}